NEW YORK (GenomeWeb) – Biocept announced today that it has signed an agreement under which its Target Selector liquid biopsy tests and services will be marketed to community-based oncologists and hematologists in the US by Miraca Life Sciences (MLS).
Under the terms of the promotion and marketing deal, Texas-based MLS will promote Target Selector testing to its new and existing clinician clients in certain unnamed sales territories in the US. Biocept will perform the tests at its CLIA lab in San Diego.
Additional terms were not disclosed.
The Target Selector technology is designed to analyze both circulating tumor cell and circulating tumor DNA biomarkers from a blood sample. Biocept offers tests for a variety of cancers including lung, breast, colorectal, gastric, skin, and prostate.
"A major objective for Biocept is to increase the adoption of our Target Selector testing services globally, and we believe that this agreement will enable us to expand our service offering in the US market," Biocept President and CEO Michael Nall said in a statement.
In April, Biocept signed a deal giving Oregon Health & Sciences University the rights to offer Target Selector testing throughout Oregon. And last year, the company signed similar agreements covering Canada, Israel, Mexico, and the Philippines.